Welcome to CDC Stacks | Update on Herpes Zoster Vaccine: Licensure for Persons Aged 50 Through 59 Years . MMWR (60) 44; 1528-1528. - 7468 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Update on Herpes Zoster Vaccine: Licensure for Persons Aged 50 Through 59 Years . MMWR (60) 44; 1528-1528.
Filetype[HTML - ]
View this content


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated Booster Dose Guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR 2011; 60 (30):1018-1019.
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    August 11, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(30):1018-9.
    Description:
    In January 2011, the Food and Drug Administration lowered the approval age range for use of MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics), a quadrivalent meningococcal conjugate vaccine, to include persons aged 2 through 55 years. One other...
    Status:
    superseded
    File Type:
    Filetype[PDF - 72.15 KB]
  2. Update on recommendations for use of herpes zoster vaccine
    Personal Author:
    Hales, Craig M.; Harpaz, Rafael; Ortega-Sanchez, Ismael; Bialek, Stephanie R.;
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.; National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.;
    Published:
    August 22, 2014
    Series:
    MMWR. Morbidity and mortality weekly report, Vol. 63, no. 33, p. 729-31
    Description:
    Herpes zoster vaccine (Zostavax [Merck & Co., Inc.]) was licensed in 2006 and recommended by the Advisory Committee on Immunization Practices (ACIP) in 2008 for prevention of herpes zoster (shingles) and its complications among adults aged ≥60 ...
    Status:
    current
    File Type:
    Filetype[PDF - 195.85 KB]
  3. Recommended Immunization Schedules for Persons Aged 0 Through 18 Years United States, 2011. MMWR 2011; 60 (05): 1-4.
    Description:
    Each year, the Advisory Committee on Immunization Practices (ACIP) publishes immunization schedules for persons aged 0 through 18 years. These schedules summarize recommendations for currently licensed vaccines for children aged 18 years and younger ...
    Status:
    superseded
    File Type:
    Filetype[HTML]
  4. Licensure of a high-dose inactivated influenza vaccine for persons aged >or= 65 years (Fluzone High-Dose) and guidance for use -- United States, 2010. MMWR 2010;59 (16): 485-486.
    Published:
    April 30, 2010
    Source:
    MMWR. Morbidity and mortality weekly report. 2010; 59(16):485-6.
    Description:
    Persons aged >or= 65 years are at greater risk for hospitalization and death from seasonal influenza compared with other age groups, and they respond to vaccination with lower antibody titers to influenza hemagglutinin (an established correlate of pr...
    Status:
    current
    File Type:
    Filetype[HTML]
  5. Recommended Immunization Schedules for Persons Aged 0 Through 18 Years --- United States, 2010. MMWR 2009; 58 (51-52): 1-4.
    Description:
    The Advisory Committee on Immunization Practices (ACIP) annually publishes an immunization schedule for persons aged 0 through 18 years that summarizes recommendations for currently licensed vaccines for children aged 18 years and younger and include...
    Status:
    superseded
    File Type:
    Filetype[HTML]